Skip to main content
TipRanks
Go Ultimate75% OFF

Innova Captab Limited (INNOVACAP) AI Stock Analysis

0 Followers
IN:INNOVACAP

Innova Captab Limited

(NSE:INNOVACAP)

Select Model
Rating:71Outperform
Price Target:INR 1,112.00â–²(10.53% Upside)
Action:reiterated
Date:10/01/26

Strong financial performance with accelerating revenue growth and balance sheet strength is the primary positive driver, reinforced by supportive technical indicators showing long-term bullish momentum; high valuation metrics provide a partial offset.

Positive Factors
Strong Revenue GrowthStrong revenue expansion indicates growing demand for Innova Captab’s pharmaceutical manufacturing and finished-dose offerings. If sustained, this scale can strengthen customer relationships, improve operating leverage, and support continued investment in production and product-development capabilities.
Negative Factors
Weak Cash Flow ConversionWeak conversion of reported earnings into operating and free cash flow is a material execution concern. Persistent reinvestment or working-capital drag can limit self-funded growth, increase reliance on external financing, and make earnings less durable if cash generation does not improve.

Innova Captab Limited (INNOVACAP) vs. iShares MSCI India ETF (INDA)

-20%0%20%40%60%80%IN:INNOVACAP+38.35%INDA-4.06%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
INR 66.31B
Dividend Yield
0.20%
Average Volume (3M)
36.81K
Price to Earnings (P/E)
34.5
Beta (1Y)
0.67
Revenue Growth
36.84%
EPS Growth
35.82%
Country
India
Employees
1,600
Sector
Healthcare
Sector Strength
51
Industry
Drug Manufacturers - Specialty & Generic

Innova Captab Limited Business Overview & Revenue Model

Company Description

Innova Captab Limited, established in Panchkula, India, in 2005, operates as a comprehensive pharmaceutical enterprise. Its operations encompass the full spectrum of drug development, from research and development and manufacturing to distribution an...

How the Company Makes Money

Innova Captab Limited primarily makes money by manufacturing and selling pharmaceutical finished dosage formulations. Its revenue model generally includes: (1) Sales of finished dosage products: income earned from supplying its own or customer-specif...

Innova Captab Limited Financial Statement Overview

Summary

Robust revenue growth accelerating to 19.6% with net income reaching 1.41 billion, improving gross margins to 22.4%, and a solid balance sheet with debt-to-equity at 0.32 offset cash flow volatility from investments.

Income Statement

85Very Positive

Balance Sheet

80Positive

Cash Flow

65Positive
Financial statement breakdown
BreakdownTTMMar 2026Mar 2025Mar 2024Mar 2023Mar 2022
Income Statement
Total Revenue17.49B16.04B12.44B10.77B9.26B8.00B
Gross Profit3.95B5.23B4.30B3.42B2.35B1.73B
EBITDA2.67B2.10B1.86B1.67B1.23B987.68M
Net Income1.54B1.41B1.28B943.45M679.54M639.53M
Balance Sheet
Total Assets018.37B15.80B13.21B10.19B5.75B
Cash, Cash Equivalents and Short-Term Investments682.50M451.54M652.81M840.92M70.25M8.75M
Total Debt03.44B3.38B2.45B2.37B1.99B
Total Liabilities-10.91B7.47B6.21B4.90B6.93B3.67B
Stockholders Equity10.91B10.91B9.59B8.31B2.77B2.09B
Cash Flow
Free Cash Flow-125.34M343.39M-1.09B-1.41B-118.67M-209.85M
Operating Cash Flow297.19M1.03B638.44M1.46B671.24M588.98M
Investing Cash Flow-354.74M-1.10B-1.52B-4.99B-908.43M-1.88B
Financing Cash Flow-92.25M-51.35M915.33M3.61B270.92M1.25B

Innova Captab Limited Technical Analysis

Technical Analysis SentimentNegative
Last Price1006.05

Price Trends

50DMA1111.74Negative
100DMA1056.33Negative
200DMA911.98Positive

Market Momentum

MACD-3.49Negative
RSI47.54Neutral
STOCH31.42Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:INNOVACAP, the sentiment is Negative. The current price of 1006.05 is below the 20-day moving average (MA) of 1042.75, below the 50-day MA of 1111.74, and above the 200-day MA of 911.98, indicating a neutral trend. The MACD of -3.49 indicates Negative momentum. The RSI at 47.54 is Neutral, neither overbought nor oversold. The STOCH value of 31.42 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:INNOVACAP.

Innova Captab Limited Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

IN:INNOVACAP against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
IN:INNOVACAPIN:INNOVACAP71OutperformINR 57.57B34.50―0.20%36.84%35.82%
IN:BLISSGVSIN:BLISSGVS69NeutralINR 70.70B44.00―0.22%24.87%46.37%
IN:GUFICBIOIN:GUFICBIO58NeutralINR 43.37B59.00―0.02%18.17%40.72%
IN:MOREPENLABIN:MOREPENLAB55NeutralINR 49.67B26.46―0.22%30.20%91.17%
IN:ORCHPHARMAIN:ORCHPHARMA55NeutralINR 56.92B554.74――10.83%-89.83%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
IN:UNICHEMLABIN:UNICHEMLAB51NeutralINR 33.80B9.96――6.44%283.10%

* Healthcare Sector Average

Performance Comparison

0%100%200%300%IN:INNOVACAPIN:BLISSGVSIN:GUFICBIOIN:MOREPENLABIN:ORCHPHARMAIN:UNICHEMLABDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
IN:INNOVACAP and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
IN:INNOVACAPInnova Captab Limited1006.05247.8532.69%
IN:BLISSGVSBliss Gvs Pharma Limited664.90505.71317.67%
IN:GUFICBIOGufic Biosciences Limited432.5079.3922.48%
IN:MOREPENLABMorepen Laboratories Limited90.6546.71106.32%
IN:ORCHPHARMAOrchid Pharma Limited950.4584.709.78%
IN:UNICHEMLABUnichem Laboratories Limited480.0512.252.62%

Innova Captab Limited Corporate Events

Innova Captab reports Q2 FY27 revenue at ₹496.3 crores

Nov 13, 2026

Innova Captab reported unaudited consolidated revenue from operations of ₹496.3 crores for Q2 FY27, up 30.5% year on year, while EBITDA rose 29.2% to ₹72.4 crores and PAT increased 43.0% to ₹42.4 crores. EBITDA margin was 14.6% and PAT margin was 8.5...

Innova Captab Files Scrutinizer’s Report and Voting Results for 22nd AGM

Oct 2, 2026

Innova Captab Limited, a listed pharmaceutical and healthcare company with operations in Panchkula and a registered office in Navi Mumbai, held its 22nd Annual General Meeting in compliance with SEBI’s Listing Regulations. The company is traded on BS...

Innova Captab Board Clears Revised Audited FY26 Results

Aug 23, 2026

Innova Captab Limited has notified the stock exchanges that its board has approved revised audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2026, following a late-night board meeting on August 2...

Innova Captab Revises FY26 Accounts and Clears Baddi Plant Expansion

Aug 22, 2026

Innova Captab Limited’s board has approved the revision of its standalone and consolidated financial statements for the financial year ended 31 March 2026, including updated audited results, balance sheets, cash flow statements, and independent audit...

Innova Captab Revises FY26 Results and Clears Baddi Capacity Expansion

Aug 22, 2026

Innova Captab Limited’s board has approved a revision of the company’s standalone and consolidated financial statements for the fiscal year 2025-26, including updated audited results, balance sheets, cash flow statements and auditor reports for the y...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 01, 2026